Monica Autiero1, 12, Johannes Waltenberger2, 12, Didier Communi1, 12, Andrea Kranz2, Lieve Moons1, Diether Lambrechts1, Jens Kroll2, Stephane Plaisance1, Maria De Mol1, Françoise Bono3, Stefanie Kliche2, Guido Fellbrich2, Kurt Ballmer-Hofer4, Domenico Maglione5, Ulrike Mayr-Beyrle2, Mieke Dewerchin1, Saskia Dombrowski2, Danica Stanimirovic6, Paul Van Hummelen1, Christoph Dehio7, Daniel J Hicklin8, Graziella Persico9, Jean-Marc Herbert3, David Communi10, Masabumi Shibuya11, Désiré Collen1, Edward M Conway1
& Peter Carmeliet11
The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KULeuven, Leuven, B-3000, Belgium.
2
Department of Internal Medicine II, Ulm University Medical Center, Ulm, D-8908, Germany.
3
Haemobiology Department, Sanofi, Cedex 31036, Toulouse, France.
4
Paul Scherrer Institute, Laboratory of Biomolecular Research Molecular Cell Biology, 5232 Villigen-PSI, Switzerland.
5
Geymonat SpA, 03012 Anagni, Italy.
6
Cellular Neurobiology Group, Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario K1A 0R6, Canada.
7
Division of Molecular Microbiology, Biozentrum of the University of Basel, Basel, CH-4056, Switzerland.
8
ImClone Systems Inc, New York, New York 10014, USA.
9
Istituto Internazionale di Genetica e Biofisica, CNR, 80125 Naples, Italy.
10
Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Free University of Brussels, B-1070 Brussels.
11
Department of Genetics, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
12
These authors contributed equally to this work.
Correspondence should be addressed to Peter Carmeliet peter.carmeliet@med.kuleuven.ac.be
